Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Beuvry – page 31

1 417 clinical trials in Beuvry, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Beuvry at a glance
1 417
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 417 trials in Beuvry

Open in trial search

Duchenne muscular dystrophy

Recruiting

Long-Term Safety and Efficacy Study of Givinostat for Patients with Duchenne Muscular Dystrophy Previously Treated with Givinostat

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Hypoxic ischaemic encephalopathy neonatal

Recruiting

Study of Autologous Cord Blood Stem Cells Treatment for Newborns with Hypoxic-Ischemic Encephalopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Sponsor:Assistance Publique Hopitaux De Marseille

Colorectal cancer

Recruiting

Study on Indocyanine Green for Reducing Leakage in Colorectal Cancer Surgery Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Centre Hospitalier Regional Universitaire

Tumour of ampulla of Vater

Recruiting

Study on Post-Surgery Antibiotic Use for Patients with Biliary Stents Undergoing Pancreaticoduodenectomy: Piperacillin and Tazobactam Evaluation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Piperacillin
  • Sponsor:Centre Hospitalier Universitaire Rouen

Ischaemic stroke

Recruiting

Study on Intra-Arterial Thrombolysis with Alteplase for Patients with Acute Ischemic Stroke in the Anterior Circulation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:CHRU De Nancy

Dermatomyositis

Recruiting

Study on Baricitinib for Patients with Relapsing or Naïve Dermatomyositis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

B-cell lymphoma+1

Recruiting

Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:LYSARC

Chronic myeloid leukaemia

Recruiting

Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier De Versailles

Chronic myeloid leukaemia

Recruiting

Study on Stopping Dasatinib in Patients with Chronic Myeloid Leukemia After a Previous Attempt to Stop Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Region Uppsala

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Placenta praevia+1

Recruiting

Study on Tranexamic Acid to Prevent Blood Loss in Women with Placenta Previa Undergoing Cesarean Delivery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Potassium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Pleural mesothelioma malignant

Recruiting

Study of Intrapleural Photodynamic Therapy with Aminolevulinic Acid Hydrochloride and Nivolumab for Patients with Malignant Pleural Mesothelioma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Beuvry

What the registry says about research in the country

01 Oncology Research - Digestive System

Several groundbreaking trials focusing on gastrointestinal cancers, including studies evaluating novel treatments for esophageal squamous cell carcinoma and advanced colorectal cancer. Research includes innovative combination therapies and targeted treatments for specific genetic mutations.

  • Esophageal Cancer Treatment
  • Colorectal Cancer Therapies
  • Pancreatic Adenocarcinoma Studies
02 Respiratory and Lung Cancer Research

Innovative studies examining treatments for non-small cell lung cancer, including immunotherapy combinations and radiation therapy approaches. Research focuses on improving outcomes for patients with advanced disease stages.

  • Advanced NSCLC Treatments
  • Immunotherapy Combinations
  • Radiation Therapy Protocols
03 Prostate and Breast Cancer Studies

Comprehensive research into hormone-dependent cancers, investigating new treatment approaches for castrate-resistant prostate cancer and ER+/HER2- breast cancer. Studies include both early-stage and advanced disease management.

  • Prostate Cancer Therapeutics
  • Breast Cancer Treatments
  • Hormone Therapy Research
04 Infectious Disease and Critical Care

Studies examining treatments for respiratory tract infections and severe infections in intensive care settings. Research includes antibiotic alternatives and management strategies for septic shock.

  • Respiratory Infections
  • Antibiotic Studies
  • Critical Care Interventions
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.